share_log

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

Benzinga ·  Apr 19, 2023 18:25

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $22 to $17.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment